Papers using
MLN51
antibodies
Papers on
MLN51
Proteasome inhibitors as experimental therapeutics of autoimmune diseases.Jansen et al., Amsterdam, Netherlands. In Arthritis Res Ther, 2014
The antiproliferative capacity of proteasome inhibitors (PIs) has received considerable attention given the success of their first prototypical representative, bortezomib (BTZ), in the treatment of B cell and plasma cell-related hematological malignancies.